TOKYO, October 21, 2021 - EPS International Holdings Co., Ltd. , the global CRO (Clinical Research Organization) with strength in Asia-Pacific clinical trials support, today announced the new President and the Executive Leadership Team, effective October 1, 2021.

 

Board of Directors

Tomohisa Hayakawa

President and Representative Director

Corporate Officers

Tomohisa Hayakawa

President and Representative Corporate Officer

Kiyoto Fujisawa

Senior Corporate Officer

Akiko Kitagawa

Corporate Officer

Noriyuki Takai

Corporate Officer

Hiroaki Sekiwa

Corporate Officer

Takihiro Hirasawa

Corporate Officer

Auditor

Takahiro Uematsu

*EPS International is the EPS group company

About EPS International and EPS group
Since its establishment in 1991 as one of pioneering CROs, EPS Group has been a Healthcare Solution Provider to pharmaceutical companies, medical device manufacturers, hospitals and clinics, and academia with various solutions from development to marketing, sales, consultation covering Asia centered in China and new values created in big data & AI, regenerative medicine, etc. The strength of EPS International lies in the fact that it has the greatest presence in Japan. In Asia, the company has multiple overseas offices and has focused particularly on solidifying its sites in the respective Asian countries, providing clinical development support services as well as SMO services.

Website:
EPS International https://www.epsi-global.com/
EPS Holdings https://www.eps-holdings.co.jp/en/
LinkedIn:
EPS International linkedin.com/eps-international

[For inquiries related to this news release]
Human Resources
E-mail: